Monday, April 18, 2016

BRIEF-Infinity Pharma announces new preclinical data for IPI-549

* Preclinical data demonstrate that ipi-549 targets immune

cells, alters immune-suppressive microenvironment

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)